Podcasts about Abstract

This week we're covering anti-intellectualism: what is it, who's involved, is there room to grow? Hope you like *light* mental lifting (don't worry I'll spot you) because we're answering all these questions and more on this week's episode of Schauer Thoughts! Stop putting off those doctors appointments and go to https://Zocdoc.com/SCHAUER to find and instantly book a top-rated doctor today.  For a limited time, get Headspace FREE for 60 days. Go to https://Headspace.com/SCHAUER Articles: Anti-intellectualism  https://www.ebsco.com/research-starters/social-sciences-and-humanities/anti-intellectualism Exploring the Reasons Behind Parental Refusal of Vaccines https://pmc.ncbi.nlm.nih.gov/articles/PMC4869767/ Information Density https://publish.obsidian.md/pkc/Hub/Theory/Sciences/information+density The Development of Concrete and Abstract Thinking Patterns  Blog post but clinically reviewed by Tiffany Lovins, Licensed Mental Health Counselor (LMHC) https://calmerry.com/blog/psychology/the-development-of-concrete-and-abstract-thinking-patterns/#:~:text=Abstract%20thinking%20and%20concrete%20thinking%20are%20two,us%20to%20make%20connections%20and%20see%20patterns Cliche's - What is a cliche? https://writingcenter.unc.edu/tips-and-tools/cliches/#:~:text=What%20is%20a%20cliché?,memorable%20contributions%20to%20your%20writing Books: The Knowledge Illusion - Steven Sloman & Philip Fernbach Quoted pages: 175 - 178 Attention: Beyond Mindfulness - Gay Watson If there are any resources I mentioned that are not listed, please let me know and I'll update ASAP. Learn more about your ad choices. Visit podcastchoices.com/adchoices

This is The Digital Story Podcast #995, April 15, 2025. Today's theme is, "Abstract Architecture." I'm Derrick Story. Opening Monologue I found myself sitting in the atrium of a Hyatt Regency looking up. I started to wonder how things would look if I were up there, looking down. What I discovered is a beautiful subject for abstract photography. I tell the story of how this all worked out on today's TDS Photography Podcast. I hope you enjoy the show.

Dr. Refky Nicola summarizes a recent review article from RadioGraphics. Find out how to stand out from the crowd and create your own outstanding exhibit.  Creating an Award-winning RSNA Education Exhibit. Albasha and Burkett et al. RadioGraphics 2022; 42:E106-E108. Check out the new RSNA Education Course about submitting an Abstract for RSNA2025. How To Prepare and Submit an Educational Abstract for the RSNA Annual Meeting (2025)    

Del The Funky Homosapien & thegoodnews "Fakebreaker"Sun Ra "The Cosmic Explorer"The Grateful Dead "Cosmic Charlie (Live)"The 13th Floor Elevators "She Lives (In A Time Of Her Own) (Live)"John Braheny "Silver Cord"Charles Mingus "Duke Ellington's Sound of Love (Live)"Pharoah Sanders "Balance"The Fall "Last Commands of Xyralothep Via M.E.S."

Default deny is an old, and very recognizable term in security. Most folks that have been in the industry for a long time will associate the concept with firewall rules. The old network firewalls, positioned between the public Internet and private data centers, however, were relatively uncomplicated and static. Most businesses had a few hundred firewall rules at most. The idea of implementing default deny principles elsewhere were attempted, but without much success. Internal networks (NAC), and endpoints (application control 1.0) were too dynamic for the default deny approach to be feasible. Vendors built solutions, and enterprises tried to implement them, but most gave up. Default deny is still an ideal approach to protecting assets and data against attacks - what it needed was a better approach. An approach that could be implemented at scale, with less overhead. This is what we'll be talking to Threatlocker's CEO and co-founder, Danny Jenkins, about on this episode. They seemed to have cracked the code here and are eager to share how they did it. This segment is sponsored by ThreatLocker. Visit https://www.securityweekly.com/threatlocker to learn more about them! We wanted security data? We got it! Now, what the heck do we DO with all of it? The core challenge of security operations, incident response, and even compliance is still a data management and analysis problem. Which is why we're seeing companies like Abstract Security pop up to address some of these challenges. Abstract just released a comprehensive eBook on security data strategy, linked below, and you don't even need to give up an email address to read it! In this interview, we'll talk through some of the highlights: Challenges Myths Pillars of a data security strategy Understanding the tools available Segment Resources A Leader's Guide to Security Data Strategy eBook In the enterprise security news, new startup funding what happened to the cybersecurity skills shortage? tools for playing with local GenAI models CVE assignment drama a SIEM-agnostic approach to detection engineering pitch for charity a lost dog that doesn't want to be found All that and more, on this episode of Enterprise Security Weekly. Visit https://www.securityweekly.com/esw for all the latest episodes! Show Notes: https://securityweekly.com/esw-402

Default deny is an old, and very recognizable term in security. Most folks that have been in the industry for a long time will associate the concept with firewall rules. The old network firewalls, positioned between the public Internet and private data centers, however, were relatively uncomplicated and static. Most businesses had a few hundred firewall rules at most. The idea of implementing default deny principles elsewhere were attempted, but without much success. Internal networks (NAC), and endpoints (application control 1.0) were too dynamic for the default deny approach to be feasible. Vendors built solutions, and enterprises tried to implement them, but most gave up. Default deny is still an ideal approach to protecting assets and data against attacks - what it needed was a better approach. An approach that could be implemented at scale, with less overhead. This is what we'll be talking to Threatlocker's CEO and co-founder, Danny Jenkins, about on this episode. They seemed to have cracked the code here and are eager to share how they did it. This segment is sponsored by ThreatLocker. Visit https://www.securityweekly.com/threatlocker to learn more about them! We wanted security data? We got it! Now, what the heck do we DO with all of it? The core challenge of security operations, incident response, and even compliance is still a data management and analysis problem. Which is why we're seeing companies like Abstract Security pop up to address some of these challenges. Abstract just released a comprehensive eBook on security data strategy, linked below, and you don't even need to give up an email address to read it! In this interview, we'll talk through some of the highlights: Challenges Myths Pillars of a data security strategy Understanding the tools available Segment Resources A Leader's Guide to Security Data Strategy eBook In the enterprise security news, new startup funding what happened to the cybersecurity skills shortage? tools for playing with local GenAI models CVE assignment drama a SIEM-agnostic approach to detection engineering pitch for charity a lost dog that doesn't want to be found All that and more, on this episode of Enterprise Security Weekly. Visit https://www.securityweekly.com/esw for all the latest episodes! Show Notes: https://securityweekly.com/esw-402

We wanted security data? We got it! Now, what the heck do we DO with all of it? The core challenge of security operations, incident response, and even compliance is still a data management and analysis problem. Which is why we're seeing companies like Abstract Security pop up to address some of these challenges. Abstract just released a comprehensive eBook on security data strategy, linked below, and you don't even need to give up an email address to read it! In this interview, we'll talk through some of the highlights: Challenges Myths Pillars of a data security strategy Understanding the tools available Segment Resources A Leader's Guide to Security Data Strategy eBook Show Notes: https://securityweekly.com/esw-402

Tune in live every weekday Monday through Friday from 9:00 AM Eastern to 10:15 AM.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Buy our NFT⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Join our Discord⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Check out our Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Check out our YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠DISCLAIMER: You should never treat any opinion expressed by the hosts of this content as a recommendation to make a particular investment, or to follow a particular strategy. The thoughts and commentary on this show are an expression of the hosts' opinions and are for entertainment & informational purposes only.

In den letzten 25 Jahren haben sich viele Frauen in den Wechseljahren aus Angst vor Brustkrebs gegen eine Hormontherapie entschieden. Aber die Risiken, die man damals berechnet hatte, galten für Frauen, die schon durch waren mit der hormonellen Umstellung. Noch dazu kommen heute sehr oft andere Wirkstoffe zum Einsatz, nämlich genau die Hormone, die der Körper selber herstellt und die deswegen als „bioidentisch“ bezeichnet werden. Auf Instagram ist oft zu lesen, dass eine Hormontherapie mit diesen Wirkstoffen das Brustkrebsrisiko nicht erhöht oder sogar senkt. Aber ist das wirklich so? Was wissen wir darüber? In dieser von Diana moderierten Folge beantwortet Mrs. Menopause Dr. Katrin Schaudig, Präsidentin der Deutschen Menopause Gesellschaft, die Frage aller Fragen – und noch einige weitere von Euch, etwa zur Rimkus-Methode, zum Lipoprotein A-Wert, und ob man auch Hormone nehmen kann, wenn man mal eine Thrombose hatte.INFOS ZUR FOLGE:Hier geht es zu den aktuellen Auflagen für den Wirkstoff Fezolinetant, wegen des Risikos einer Leberschädigung.Hier geht es zum Abstract (der Zusammenfassung) der E3N-Studie, hier zum ganzen Text. Die entscheidende Tabelle ist Tabelle 3.Dr. Katrin Schaudig erwähnt immer wieder den Wirkstoff Dydrogesteron: Er ist dem Progesteron sehr ähnlich, aber macht nicht so matschig. Mehr Infos gibt es auch in der Folge „HRT – how to“Hier geht es zum Text aus der Süddeutschen Zeitung, über den sich die MENO-Aktivistinnen so aufgeregt haben.Hier geht es zu Dr. Katrin Schaudig im Internet.Hier geht es zu Dr. Katrin Schaudig auf Instagram.Hier geht es zur Deutschen Menopause Gesellschaft, deren Präsidentin Dr. Katrin Schaudig ist. Dort gibt es auch die Aufzeichnungen der Patientinnenveranstaltungen der Fachgesellschaft (aus der Reihe: „Wissen macht cool“), also richtig gute Infos von Topp-Leuten.Hier geht es zum Newsletter "Saisonwechsel" von der BRIGITTE.Hier geht es zum neuen meno_brigitte-Insta-Account.Hier geht es zu Dianas Instagram.Hier geht es zu Julias Instagram.Ihr habt Anregungen, wollt uns Eure Geschichte erzählen oder selbst bei uns zu Gast im Podcast sein? Dann schreibt uns beiden persönlich, worüber Ihr gern mehr wissen würdet, was Euch bewegt, rührt, entsetzt und Freude macht an podcast@brigitte.de. Wir freuen uns auf Euch! Und bewertet und abonniert unseren Podcast gerne auch auf Spotify, iTunes, Amazon Music oder Audio Now. Noch mehr spannende Beiträge findet Ihr zudem auf Brigitte.de sowie dem Instagram- oder Facebook-Account von BRIGITTE –schaut vorbei! +++ Weitere Infos zu unseren Werbepartnern finden Sie hier: https://linktr.ee/menoanmich.podcast ++++++Unsere allgemeinen Datenschutzrichtlinien finden Sie unter https://datenschutz.ad-alliance.de/podcast.html +++Wir verarbeiten im Zusammenhang mit dem Angebot unserer Podcasts Daten. Wenn Sie der automatischen Übermittlung der Daten widersprechen wollen, klicken Sie hier: https://datenschutz.ad-alliance.de/podcast.htmlUnsere allgemeinen Datenschutzrichtlinien finden Sie unter https://art19.com/privacy. Die Datenschutzrichtlinien für Kalifornien sind unter https://art19.com/privacy#do-not-sell-my-info abrufbar.

You asked, so I'm answering girl—how the hell do we fuel properly for sprinting? There's a lot of noise out there. Some say “sprints are short, so you don't need much.” But if you've ever sprinted properly—I mean real, all-out, full-body-on-fire kind of sprinting—you'll know that's not true. In this EP, I break down the exact science behind the three energy systems your body uses when sprinting (yes, three—not just one), and then I walk you through how I actually fuel for sprint sessions. I'm talking about real strategy—not theory—what I eat, when I eat it, and why. I'll show you how fuelling well can make the difference between power and burnout. Between flying and flailing. If you're training for performance (or aesthetics), this is a game-changer. Key Takeaways: What energy systems power sprinting (ATP-PCr, glycolytic, and aerobic) Why creatine and carbohydrates are essential for short, explosive efforts What to eat before, during, and after a sprint session for peak performance The difference between fuelling for general training vs sprint-specific sessions How under-fuelling kills your power output and stalls your progress A step-by-step breakdown of my own pre-, intra-, and post-sprint fuelling strategy Why most women aren't actually sprinting hard enough to need advanced fuelling—but how to work up to it How to personalise your sprint fuelling plan based on your intensity, duration, and recovery needs Quotes: “Trying to sprint without fuel is like pushing the gas pedal with an empty tank—it splutters and stalls. That's your body under-fueled.” “It's not just about pre-workout meals. How you fuel across the day—and week—builds your power, not just your plate.” “You don't earn power with discipline. You earn it with precision—and food is part of that precision.” “Most women aren't sprinting hard enough to need intra-workout fuel. But if you are? A couple of dates and some EAAs might just change the game.” “Science is great—but experience is better. I've spent the last year testing this on my own body. Here's what works.” Studies, Research & Protocols Mentioned Smith-Ryan, A.E., Fukuda, D.H., Stout, J.R., et al. (2021). "Creatine Supplementation in Women's Health: A Lifespan Perspective." Published in Nutrients, 13(3): 877.

During the pandemic, Debbie Taylor-Kerman made a big decision. She decided to quit her settled career in the commercial art licensing industry to become a full-time artist. Her most recent work is the subject of a new exhibition at Heath Gallery, "More Love Now", on view through May 3. Taylor-Kerman discusses her story, including her childhood in Scotland to arriving to New York in 1991. She will be hosting an Artist Talk at Heath Gallery on April 12 from 2-4pm.

…

Coucou ! Bienvenue sur ce nouvel épisode de CHER BON!, je suis Louison Lagneaux, et je vous propose de partir à la rencontre de celles et ceux qui travaillent le bon et qui font du bien !❤️‍

Slowdive "Blue Skied An' Clear"My Bloody Valentine "Don't Ask Why"Black Sabbath "Solitude"Om "Sinai"Boris with Merzbow "Feedbacker"Cathedral "Imprisoned In Flesh"

Creating sketches for paintings is an essential step in the artistic process, serving as a foundational tool that guides artists from initial concept to completed artwork. Through sketching, artists explore composition, proportions, light, and shadow, often refining ideas and experimenting freely without the pressure of permanence. These preliminary drawings allow the painter to visualize the final piece, test different arrangements, and solve potential artistic challenges before applying paint to canvas. Additionally, sketches capture spontaneous inspirations and emotions, preserving the initial creative impulse. By investing time in thoughtful, well-developed sketches, artists ensure clarity in their vision, ultimately enhancing the depth, quality, and cohesiveness of their finished paintings.

Sun, 30 Mar 2025 12:19:06 +0000 https://gedanken-lauschen.podigee.io/20-new-episode 58296d652b2c94e7af12d1a5dba6d57e Im Gespräch mit dem Philosophen Konstantin Deininger über seine Dissertation im Bereich der Tierethik Konstantin Deininger hat jüngst die Doktorurkunde für seine Promotion an der Universität Wien zu einem tierethischen Thema verliehen bekommen. Ich habe ihn in den Podcast eingeladen, weil ich erfahren wollte, was es genau mit dem Konzept des Mitgeschöpfs auf sich hat. Diesen Begriff bringt die US-amerikanische Philosophin Cora Diamond in die tierethische Debatte ein und sie macht damit nicht nur auf die Ähnlichkeiten zwischen Mensch und Tier aufmerksam, sondern vor allem auf etwas, das sich unserer Betrachtung immer entziehen wird. Etwas, das sich nicht konzeptionalisieren lässt. Durch diese Andersartigkeit oder Wundersamkeit, die das Tier als Mitgeschöpf (Fellow creature) für uns immer bereit hält, können wir zum einen Kriterien des Menschseins besser verstehen und zum anderen das Bemächtigen gegenüber allem Nichtmenschlichen hinterfragen. Oder wie es Konstantin Deininger im Abstract seiner Dissertation beschreibt: "Tiere als Mitgeschöpfe zu begreifen, impliziert, sie nicht nur in ihrer Ähnlichkeit, sondern auch in ihrer Differenz zum Menschen als moralisch relevant zu begreifen." in: Approaching Questions in (Animal) Ethics from Within: Drawing on Cora Diamond's Moral Philosophy; 2024: S. 6 Die Gründe, die Konstantin Deininger dazu gebracht haben, im Bereich der Tierethik zu forschen, sind sowohl theoretischer als auch praktischer Natur. Zum einen begeistert ihn, wie wir das Menschsein aus dem Tierlichen begreifen können und zum anderen treibt ihn auch die Frage um, wie wir mit Tieren, zu denen wir stets in einem interdependenten Abhängigkeitsverhältnis stehen, umgehen sollten. Viel Spaß bei der Folge! tierethik #philosophie #philosophieren full Im Gespräch mit dem Philosophen Konstantin Deininger über seine Dissertation im Bereich der Tierethik no

A new track by DJ Habett from the album "It felt like another fever" (2025-03-29). Tags: Beats, Sampler, Lateral, Omni, Abstract, Drums, Bass, Relief CC(by). Production notes: Quick andquite dirty ambient beat. Felt abstract but has gone a long way as of BPM. Took too much compressor and too much psychosis to hide the sample.

MoMA has just opened a major retrospective of artist Jack Whitten. “Jack Whitten: The Messenger” features more than 175 works spanning the 1960s to the 2010s. Whitten, who died in 2018, was known for his bold abstraction and deep exploration of materiality. MoMA Curator Michelle Kuo and Whitten's daughter and archive steward Mirsini Amidon discuss the show, on view through August 2.

Join Sam and Ellie as they chat with artist Lucy Sheffield about liberating life from alcohol, embracing your inner creativity, and following the nudges to a beautiful present and sober life!

Jeremy Podolnick, MD chats with David Forsh about the paper entitled "Single Screw Fixation Compared with Double Screw Fixation for Medial Malleolar Fractures: A Prospective Randomized Trial" from JOT 2018 Buckley et al. Abstract link: J Orthop Trauma . 2018 Nov;32(11):548-553. doi: 10.1097/BOT.0000000000001311. For additional educational resources visit OTA.org

For episode 197, we're excited to welcome José Ignacio Trajtenberg, CEO and Co-Founder of Xcapit. Based in Argentina, José leads a powerhouse Web3 R&D firm using blockchain and AI to build digital infrastructure for inclusion and impact. From tokenizing renewable energy, to designing wallets that function offline in low-connectivity regions, to partnering with UNICEF for financial inclusion, Xcapit is redefining what's possible when tech is designed with people—and the planet—in mind. If you're building or dreaming of building a Web3 project with real-world impact, this one is a must-listen.In this episode, you'll learn:How blockchain and AI can work together to supercharge sustainable development initiatives.Why real-world asset tokenization could be the next trillion-dollar frontier—and how it can be used for good.How decentralized tech can unlock financial inclusion, even in the most remote communities.--Key Takeaways--

01:00 People are turning to AI chatbots for empathy and advice, https://www.axios.com/2025/03/23/empathy-chatbot-turing-therapist 04:00 2Way: “He Is Salting the Earth”: Trump's “Coming In and Laying Waste to These People With the Sword”, https://www.youtube.com/watch?v=B0V9iSiTgeg 15:00 Axios: The robot empathy divide, https://www.axios.com/2025/03/23/empathy-chatbot-turing-therapist 17:00 FT: My date used AI to psychologically profile me. Is that OK?,https://www.ft.com/content/b21eaff7-7189-49a2-b791-209e8de98494 26:15 Michael joins to discuss online dating, https://x.com/Michaelmvlog 28:00 Trump vs the institutions 46:00 I asked AI to psychologically profile me, https://lukeford.net/blog/?p=160253 50:00 “They Turned Around and Bent Over”: Trump Forces Liberal Law Firm Paul Weiss To Surrender, https://www.youtube.com/watch?v=FkgPN1ysq9M 52:00 What are the top 5 right-wing institutions in America?, https://lukeford.net/blog/?p=160265 1:05:45 Loser of the Week? Democratic Law Firm Paul Weiss That Caved To Trump: “They've Destroyed America”, https://www.youtube.com/watch?v=fAQPyQVnPrA 1:07:30 Stephen Miller has the juice, https://www.youtube.com/watch?v=GGXQZVZHzLE 1:23:50 NYT: Stephen Miller, Channeling Trump, Has Built More Power Than Ever, https://www.nytimes.com/2025/01/16/us/politics/stephen-miller-trump.html 1:27:00 What's more important? Abstract principles or concrete interests? I've changed my mind on this. 1:35:00 Aaron Renn: How the Right is Finally Learning to Take Over Institutions: The right is moving beyond defensive strategies to deploy aggressive takeovers of existing institutions, https://www.aaronrenn.com/p/institutions-and-the-right 1:40:20 Andrew Weissmann in Crosshairs as War on Big Law Continues, https://www.racket.news/p/listen-to-this-article-exclusive 1:42:40 How Trump Is Scaring Big Law Firms Into Submission, https://www.youtube.com/watch?v=2dcCjp2Ad2c 2:12:00 NYT: With New Decree, Trump Seeks to Cow the Legal Profession - A presidential memorandum aimed at lawyers everywhere struck a menacing tone., https://www.nytimes.com/2025/03/22/us/politics/trump-memo-lawyers.html 2:19:40 Ann Coulter talks to Heather MacDonald, https://anncoulter.substack.com/p/the-incomparable-heather-mac-donald 2:27:00 What does your sex life say about your character? 2:37:30 The chthonic realm 2:39:00 Gashmius and Ruchnius, https://guardyoureyes.com/articles/chizuk/item/difference-between-gashmius-and-ruchnius 2:44:35 The Battle Of Narratives | View from the Danube, https://www.youtube.com/watch?v=p7J4tRUhmAg 2:47:00 Philosopher Peter Boghossian on George Floyd, https://en.wikipedia.org/wiki/Peter_Boghossian 2:55:30 Amy Wax talks to Ann Coulter about affirmative action, https://anncoulter.substack.com/p/my-most-politically-incorrect-interview 3:08:00 Talking to Grok about Noticing: An Essential Reader (1973-2023), https://lukeford.net/blog/?p=160212 3:24:00 Trump's 2025 seeks to reverse LBJ's 1965, https://www.axios.com/2025/03/22/trump-2025-reverse-lbj-1965-civil-rights-poverty 3:28:00 Biden Joint Chiefs Pick To Purge White Men from Officer Corps., https://anncoulter.substack.com/p/biden-nominee-for-joint-chiefs-chair 3:29:00 Next Chairman of Joint Chiefs Wants White Male Officers to be a Minority, https://www.danielgreenfield.org/2023/05/next-chairman-of-joint-chiefs-wants.html 3:30:00 When Race Trumps Merit: How the Pursuit of Equity Sacrifices Excellence, Destroys Beauty, and Threatens Lives, https://www.amazon.com/When-Race-Trumps-Merit-Sacrifices/dp/B0BXFBLY9M/ 3:33:45 He Called America Racist, Now He's in Charge of Our Nukes, https://www.frontpagemag.com/he-called-america-racist-now-hes-charge-our-nukes-daniel-greenfield/

In this episode, Gaby and Andreina learn more about the French artist Camille Claudel (1864-1943) by watching two films portraying different times in her life: Camille Claudel (1988) and Camille Claudel 1915 (2013). Claudel became one of the most acclaimed sculptors of her time through prodigious ability and drive. However, in popular imagination, she is most often remembered as August Rodin's lover, a secondary character in the history of one of France's greatest artists.Gaby and Andreina discuss how Camille Claudel is portrayed in both films and how the artistic dimension of her life is represented: Do these two films succeed in portraying Claudel in all her dimensions, including as a woman and an artist? Listen to this special episode, the third in our series dedicated to artists and their art in film. Links and sources: Abstract of the article “Camille Claudel: trajectory of a psychosis” The Art Institute of Chicago: Member Lecture: Camille ClaudelCamille Claudel through Five WorksCamille Claudel, Bust of RodinAugust Rodin, Thought (Camille Claudel)

In this episode, Andreina and Gabriela learn more about the French sculptor Camille Claudel (1864-1943), through two films: Camille Claudel (1988) and Camille Claudel 1915 (2013).An artistic prodigy from a very young age, Claudel gained recognition and acclaim as an artist during her lifetime. However, in the popular imagination, she is most often remembered as Auguste Rodin's lover.Andreina and Gabriela discuss how Camille Claudel is portrayed in the two movies and how her dimension as a female artist and woman in a male-dominated art practice is conveyed: do the films give us a good sense of who she was as an artist?Join us in this third episode of our series of discussions about artists and their art in film.Links and sources:Abstract of article “Camille Claudel: trajectory of a psychosis”The Art Institute of Chicago: Member Lecture: Camille ClaudelCamille Claudel through Five WorksCamille Claudel, Bust of RodinAugust Rodin, Thought (Camille Claudel)

Jon Jordan and BlockchainGamer.biz editor Jenny Jordan talk through the week's news including:[2:07] GDC 2025 was quiet and not just for web3 gaming.[4:06] Immutable's financials for the period FY22/23 were released. [5:13] It lost $50 million on revenue of $27 million.[6:20] This compared to a loss of $31 million on sales of $19 million in FY21/22.[8:35] It still has around $140 million in cash and liquid crypto in the bank.[15:05] Immutable's revenues are rising but clearly it also needs to cut costs and have a hit game. [17:43] At least six blockchain games are now developing for console.[26:17] Gabe Leydon was talking up Apptokens at GDC 2025. Jon loves Apptokens. [30:26] Other blockchain games are already using similar features to those in the Apptokens standard.[33:20] Gabe's view is that crypto has become web2-focused. It needs to be less focused on CEXs.[36:04] Jurassic Park dinos are coming to The Sandbox in Alpha Season 5. [40:24] YGG is launching a simple Pudgy Penguins-themed Monopoly Go-style game on Abstract.

In this episode, Andreina and Gabriela learn more about the French sculptor Camille Claudel (1864-1943), through two films: Camille Claudel (1988) and Camille Claudel 1915 (2013).An artistic prodigy from a very young age, Claudel gained recognition and acclaim as an artist during her lifetime. However, in the popular imagination, she is most often remembered as Auguste Rodin's lover.Andreina and Gabriela discuss how Camille Claudel is portrayed in the two movies and how her dimension as a female artist and woman in a male-dominated art practice is conveyed: do the films give us a good sense of who she was as an artist?Join us in this third episode of our series of discussions about artists and their art in film.Links and sources:Abstract of article “Camille Claudel: trajectory of a psychosis”The Art Institute of Chicago: Member Lecture: Camille ClaudelCamille Claudel through Five WorksCamille Claudel, Bust of RodinAugust Rodin, Thought (Camille Claudel)

In this episode, Gaby and Andreina learn more about the French artist Camille Claudel (1864-1943) by watching two films portraying different times in her life: Camille Claudel (1988) and Camille Claudel 1915 (2013). Claudel became one of the most acclaimed sculptors of her time through prodigious ability and drive. However, in popular imagination, she is most often remembered as August Rodin's lover, a secondary character in the history of one of France's greatest artists.Gaby and Andreina discuss how Camille Claudel is portrayed in both films and how the artistic dimension of her life is represented: Do these two films succeed in portraying Claudel in all her dimensions, including as a woman and an artist? Listen to this special episode, the third in our series dedicated to artists and their art in film. Links and sources: Abstract of the article “Camille Claudel: trajectory of a psychosis” The Art Institute of Chicago: Member Lecture: Camille ClaudelCamille Claudel through Five WorksCamille Claudel, Bust of RodinAugust Rodin, Thought (Camille Claudel)

In this episode, we delve into the key clinically relevant abstracts in leukemia and myeloid neoplasms with Dr. Jayastu Senapati from the MD Anderson Cancer Center. Here are the links to the abstracts we discussed: Older AML: Ven+HMA vs 7+3Abstract 450: https://ash.confex.com/ash/2024/webprogram/Paper210320.htmlAbstract 971: https://ash.confex.com/ash/2024/webprogram/Paper202801.htmlAbstract 969: https://ash.confex.com/ash/2024/webprogram/Paper199267.htmlVenetoclax resistance mechanismshttps://pubmed.ncbi.nlm.nih.gov/39478230/FLAG-GO vs FLAG-IDA https://ashpublications.org/blood/article/144/Supplement%201/1513/532742/Gemtuzumab-Ozogamicin-Added-to-Fludarabine CPX-351: Abstract 55: https://ash.confex.com/ash/2024/webprogram/Paper207094.htmlAbstract 60: https://ash.confex.com/ash/2024/webprogram/Paper200413.htmlMenin Inhibitors Abstract 211 https://ash.confex.com/ash/2024/webprogram/Paper194384.htmlAbstract 212 https://ash.confex.com/ash/2024/webprogram/Paper207106.htmlAbstract 213 https://ash.confex.com/ash/2024/webprogram/Paper194827.htmlAbstracts 214 https://ash.confex.com/ash/2024/webprogram/Paper198218.htmlAbstract 215 https://ash.confex.com/ash/2024/webprogram/Paper198218.htmlAbstract 216 https://ash.confex.com/ash/2024/webprogram/Paper204375.html FLT3 inhibitors Abstract 221: https://ash.confex.com/ash/2024/webprogram/Paper201595.html MDS Abstract 349: https://ash.confex.com/ash/2024/webprogram/Paper194510.html ATRA in MDS:  https://ash.confex.com/ash/2024/webprogram/Paper200433.html  

HT2199 - Abstract Moments Yesterday we had a visitor who is not a photographer, but it's fascinated by the photographs she can make with her iPhone. Understandable, she's probably one of millions. She showed me a photograph of an abstract that was quite lovely. She had sprinkled comet all across her bathtub in preparation for a good cleaning and it made a gorgeous colored pattern. She inadvertently confirmed that abstracts are everywhere, and available to everyone.

Southern California Homebrewers Festival is right around the corner and Drew sits down with Andy Carter to discuss the Fest and this year's Bragging Rights Only Competition. In the brewery, Drew gets a bit abstract with a class about Abstrax … Continue reading →

Will empathy bring about the downfall of civilization like some argue?  Or will it bring healing?  Keeping love of humanity in the abstract is in stark contrast with Jesus' telling of the parable of the Good Samaritan.  He shows that love is real, it is put into action, and it impacts real people.  Pastor Matthew's sermon is based on Luke 10:25-42.

Cindy Lee "To Heal This Wounded Heart"Motorpsycho "Dead Of Winter"The Limiñanas feat Jon Spencer "Degenerate Star"Crosby, Stills & Nash "I Give You Give Blind"Children Of The Mushroom "Vortex"Ball "Groupies"George Brigman "Easy Stranger"Joe Prichard and Gibraltar "The Machine Is Small"Grateful Dead "Looks Like Rain"King Crimson "Moonchild"Milton Nascimento & Lô Borges "Lilia"

In this episode, we are joined by Stacey Doyon, President-Elect of the International Federation of Societies for Hand Therapy. Stacey shares with us information about IFSHT, their mission and how they are connecting upper extremity therapists across the globe. We also briefly discuss the upcoming IFSSH-IFSHT Triennial Congress being held March 24-28, 2025, in Washington, DC. Silent Auction Link: https://ifsht.org/awards_grants/silent-auction/Guest Bio: I have served on the board of the American Society of Hand Therapists from 1999-2008 which includes the following positions: Past president (2008), President (2007), President Elect (2006), Vice President (2005), Director of Advocacy (2004), Secretary/Treasurer (2003), Secretary/Treasurer elect (2002), Division Director of Alliances (2001), Division Director of Member Services (2000) and Board Member at Large (1999-2000). From 2008-2010 I was the Chairperson for the 2010 International Federation of Societies for Hand Therapy, for the American Society of Hand Therapists. In 2011 I became a board member for the Hand Therapy certification Commission holding the position of Treasurer in 2017-2024. I was a committee member since from 2006-2024. I have also served on several committees for IFSHT which include the finance committee for 2007, 2018-2019, Abstract review committee for 2013 and 2016 and then the nominations committee in 2016. In 2019-2022 I was Treasurer for IFSHT and in 2022-present I became President-Elect. I will go on to be President of IFSHT at the end of the Triennial congress in Washington DC 2025.

CancerNetwork®, in collaboration with The American Society for Transplantation and Cellular Therapy (ASTCT), organized an X Space hosted by Rahul Banerjee, MD, FACP, an assistant Professor in the Clinical Research Division at the Fred Hutchinson Cancer Center in Seattle, Washington, and Shernan Holtan, MD, the chief of Blood and Marrow Transplantation and professor of Medicine at Roswell Park Comprehensive Cancer Center.  The conversation took place during the 2025 Tandem Meeting and highlighted many significant presentations and posters on CAR T-cell therapies and transplantation, Banerjee's and Holtan's respective areas of expertise. The following trials were discussed: LBA1 - Phase II Multicenter Trial of Idecabtagene Vicleucel (Ide-cel) Followed By Lenalidomide Maintenance for Multiple Myeloma Patients with Sub-Optimal Response after an Upfront Autologous Hematopoietic Cell Transplantation: Top Line Results from the BMT CTN 1902 Clinical Trial1 “This [study] is nice because it merges 2 worlds. It's like a tandem—but not really a tandem—because you're not doing 2 transplants back-to-back. You're doing a transplant followed by CAR T-cell therapy,” said Banerjee. Abstract 50 - CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium2 “In a relatively small cohort, [investigators] found no difference in 9-month survival whether someone got their [CAR T cells] in second-line therapy vs third-line therapy from a statistical perspective. If you look at the curves, it looks like there is a potential benefit to second-line therapy, but there was not enough statistical power to determine a difference,” said Holtan. Poster 340 - CD83 Expression By Human Breast Cancer Mediates Effective Killing By CAR T3 “If there's a way to do [the therapy] armored and have a paracrine delivered in real time—and not given to the whole body—[so] the patient [would] have all the adverse effects and cytokine release syndrome release on their own…that would be awesome,” stated Banerjee.  Poster 317 - Risk Factors for Immune Effector Cell-Associated Enterocolitis (IEC-colitis) in Patients with Relapsed Myeloma Treated with Ciltacabtagene Autoleucel (cilta-cel)4 “From the best that we can tell, ironically, corticosteroids aren't the fix that we want them to be [for immune effector cell-associated colitis]…We were like ‘Diarrhea, whatever. Let's give some steroids and treat it like gut graft-versus-host-disease,' but these patients [didn't] respond as well [to that],” said Banerjee. Poster 572 - Post-CAR-T Driving Restrictions Appear Unnecessary after Week 4: Data from the US Multiple Myeloma Immunotherapy Consortium5 “Patients and their caregivers [who have] put their life aside for 4 weeks just to get through CAR T-cell therapy and the Risk Evaluation and Mitigation Strategies requirements are now being told ‘You're free to go, but you can't drive for 4 weeks, which means you can't get your own groceries or…go to doctor's appointments by yourself.' Basically, we argue…that this [requirement] is not evidence-based,” stated Banerjee.  Presentation 58 - Physical Function Measures Identify Non-Hodgkin Lymphoma Patients at High Risk of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) and 1-Year Mortality after Chimeric Antigen Receptor T (CAR-T) Cell Therapy6 “This [presentation] highlights that even within a high [CAR-HEMATOTOX group], those patients were at extraordinarily high risk of not benefitting from CAR T-cell therapy, and these tests are so simple to do. It's going to be interesting to see if others can reproduce this,” said Holtan. Poster 618 - Comparison of Outcomes after Hematopoietic STEM Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) Patients Older or Younger THAN 65 YEARS Old. a Retrospective Analysis of the Latin America Registry7 “My personal hope for this space is that our field can come up with more novel conditioning regimens such that we can ablate the marrow without causing those gastrointestinal toxicities or other organ toxicities [while] doing that so effectively that we don't even need maintenance therapies for a lot of conditions,” stated Holtan. Presentation 39 - Determinants of Immune Suppression Discontinuation in the Modern Era: A CIBMTR Analysis of 18,642 Subjects8 “I'm going to make a provocative prediction for the next paper [approximately 10 years from now]. I predict that steroids won't be the first-line therapy for acute or chronic graft-versus-host-disease,” Holtan said. Poster 516 - Patient Experiences with Chronic Graft-Versus-Host Disease and Its Treatment in the United States: A Retrospective Social Media Listening Study9 “We can still work together to make life as good as we possibly can [for patients], to improve physical function, to take away some of this mental distress, and then work together for advocacy too. [We can] help with peer support, help with resources, and help relieve some of that misunderstanding in the community,” stated Holtan. References 1.        Garfall AL, Pasquini MC, Bai L, et al. Phase II multicenter trial of idecabtagene vicleucel (ide-cel) followed by lenalidomide maintenance for multiple myeloma patients with sub-optimal response after an upfront autologous hematopoietic cell transplantation: top line results from the BMT CTN 1902 clinical trial. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Abstract LBA-1. 2.        Rojek AE, Ahmed N, Gomez-Llobell M, et al. CAR T cell therapy in early relapsed/refractory large B-cell lymphoma: real world analysis from the cell therapy consortium. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Abstract 50. 3.        Betts BC, Davilla ML, Linden AM, et al. CD83 expression by human breast cancer mediates effective killing by CAR T. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Poster ID 340. 4.        Chang Lim KJ, Chhabra S, Corraes ADMS, et al. Risk factors for immune effector cell-associated enterocolitis (IEC-colitis) in patients with relapsed myeloma treated with ciltacabtagene autoleucel (cilta-cel). Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Poster ID 317. 5.        Banerjee R, Richards A, Khouri J, et al. Post-CAR-T driving restrictions appear unnecessary after week 4: data from the US multiple myeloma immunotherapy consortium. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Poster ID 572. 6.        Herr M, McCarthy P, Jacobsen H, et al. Physical function measures identify non-Hodgkin lymphoma patients at high risk of immune effector cell-associated neurotoxicity syndrome (ICANS) and 1-year mortality after chimeric antigen receptor T (CAR-T) cell therapy. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Presentation ID 58. 7.        Duarte FB, Garcia YDO, Funke VAM, et al. Comparison of outcomes after hematopoietic STEM cell transplantation (HCT) for myelodysplastic syndrome (MDS) patients older or younger THAN 65 YEARS Old. A retrospective analysis of the Latin America registry. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Poster ID 618. 8.        Pidala J, DeFlilipp Z, DeVos J, et al. Determinants of immune suppression discontinuation in the modern era: a CIBMTR analysis of 18,642 subjects. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Presentation ID 39. 9.        Cowden M, Derrien-Connors C, Holtan S, et al. Patient experiences with chronic graft-versus-host disease and its treatment in the United States: A retrospective social media listening study. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Poster ID 516.

Dr. Neeraj Agarwal and Dr. Peter Hoskin discuss key abstracts in GU cancers from the 2025 ASCO Genitourinary Cancers Symposium, including novel therapies in prostate, bladder, and kidney cancer and the impact of combination therapies on patient outcomes. TRANSCSRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, the director of the Genitourinary Oncology Program and professor of medicine at the Huntsman Cancer Institute at the University of Utah, and editor-in-chief of ASCO Daily News. Today, we'll be discussing practice-informing abstracts and other key advances in GU oncology featured at the 2025 ASCO Genitourinary Cancers Symposium. Joining me for this discussion is Dr. Peter Hoskin, the chair of this year's ASCO GU Symposium. Dr. Hoskin is a professor in clinical oncology in the University of Manchester and honorary consultant in clinical oncology at the Christie Hospital, Manchester, and University College Hospital London, in the United Kingdom. Our full disclosures are available in the transcript of this episode. Peter, thank you for joining us today. Dr. Peter Hoskin: Thank you so much, Neeraj. I am very pleased to be here. Dr. Neeraj Agarwal: The GU meeting highlighted remarkable advancements across the spectrum of GU malignancies. What stood out to you as the most exciting developments at the ASCO GU Symposium?  Dr. Peter Hoskin: The theme of this year's meeting was "Driving Innovation, Improving Patient Care," and this reflected ASCO GU's incredible milestone in GU cancer research over the years. We were thrilled to welcome almost 6,000 attendees on this occasion from over 70 countries, and most of them were attending in person and not online, although this was a hybrid meeting. Furthermore, we had more than 1,000 abstract submissions. You can imagine then that it fostered fantastic networking opportunities and facilitated valuable knowledge and idea exchanges among experts, trainees, and mentees. So, to start I'd like to come back to you for a second because the first day started with a focus on prostate cancer and some of the key clinical trials. And congratulations to you, Neeraj, on sharing the data from the TALAPRO-2 trial, which we were eagerly awaiting. I'd love to get your thoughts on the data that you presented. Could you tell us more about that trial, Abstract LBA18?  Dr. Neeraj Agarwal: Yes, Peter, I agree with you. It was such an exciting conference overall and thank you for your leadership of this conference. So, let's talk about the TALAPRO-2 trial. First of all, I would like to remind our audience that the combination of talazoparib plus enzalutamide was approved by the U.S. FDA in June 2023 in patients with metastatic castration-resistant prostate cancer harboring HRR gene alterations, after this combination improved the primary endpoint of radiographic progression-free survival compared to enzalutamide alone in the randomized, double-blind, placebo-controlled, multi-cohort phase 3 TALAPRO-2 trial. In the abstract I presented at ASCO GU 2025, we reported the final overall survival data, which was a key alpha-protected secondary endpoint in cohort 1, which enrolled an all-comer population of patients with mCRPC. So, at a median follow-up of around 53 months, in the intention-to-treat population, the combination of talazoparib plus enzalutamide significantly reduced the risk of death by 20% compared to enzalutamide alone, with a median OS of 45.8 months in the experimental arm versus 37 months in the control arm, which was an active control arm of enzalutamide. This improvement was consistent in patients with HRR alterations with a hazard ratio of 0.54 and in those with non-deficient or unknown HRR status, with a hazard ratio of 0.87. In a post hoc analysis, the hazard ratio for OS was 0.78 favoring the combination in those patients who did not have any HRR gene alteration in their tumors by both tissue and ctDNA testing. Consistent with the primary analysis, the updated rPFS data also favored the experimental arm with a median rPFS of 33.1 compared to 19.5 months in the control arm, and a hazard ratio of 0.667. No new safety signals were identified with extended follow-up. Thus, TALAPRO-2 is the first PARP inhibitor plus ARPI study to show a statistically significant and a clinically meaningful improvement in OS compared to standard-of-care enzalutamide as first-line treatment in patients with mCRPC unselected for HRR gene alterations. Dr. Peter Hoskin: Thank you, Neeraj. That's a great summary of the data presented and very important data indeed. There was another abstract also featured in the same session, Abstract 20, titled “Which patients with metastatic hormone-sensitive prostate cancer benefit more from androgen receptor pathway inhibitors? STOPCAP meta-analyses of individual participant data.” Neeraj, could you tell us more about this abstract? Dr. Neeraj Agarwal: Absolutely, I would be delighted to. So, in this meta-analysis, Dr. David Fischer and colleagues pooled individual participant data from different randomized phase 3 trials in the mHSPC setting to assess the potential ARPI effect modifiers and determine who benefits more from an ARPI plus ADT doublet. The primary outcome was OS for main effects and PFS for subgroup analyses. Prostate cancer specific survival was a sensitivity outcome. The investigators pooled data from 11 ARPI trials and more than 11,000 patients. Overall, there was a clear benefit of adding an ARPI on both OS and PFS, with hazard ratios of 0.66 and 0.51, respectively, representing a 13% and 21% absolute improvement at 5 years, respectively, with no clear difference by the class of agent. When stratifying the patients by age group, the effects of adding an ARPI on OS and PFS were slightly smaller in patients older than 75, than in those younger than 65, or aged between 65 and 75 years. Notably, in the trials assessing the use of abiraterone, we saw very little OS effects in the group of patients older than 75, however there was some benefit maintained in prostate-cancer specific survival, suggesting that other causes of death may be having an impact. The effects of the other ARPIs, or ‘lutamides' as I would call them, were similar across all three age subgroups on both OS and PFS. Therefore, the majority of patients with mHSPC benefit from the addition of ARPIs, and the benefits/risks of abiraterone and other ‘amides' must be considered in older patients.  Dr. Peter Hoskin: Thanks, Neeraj. Another great summary relevant to our day-to-day practice. Of course, there's ongoing collection of individual patient data from other key trials, which will allow robust comparison of ARPI doublet with triplet therapy (including docetaxel), guiding more personalized treatment.   Dr. Neeraj Agarwal: I agree with you, Peter, we need more data to help guide personalized treatment for patients with mHSPC and potentially guide de-escalation versus escalation strategies. Now, moving on to a different setting in prostate cancer, would you like to mention Abstract 17 titled, “Overall survival and quality of life with Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901),” presented by Dr. Louise Emmett? Dr. Peter Hoskin: Of course I will. So, ENZA-p was a multicenter, open-label, randomized, phase 2 trial conducted in Australia. It randomized 163 patients into adaptive doses (2 or 4 cycles) of Lu-PSMA-617 plus enzalutamide versus enzalutamide alone as first-line treatment in PSMA-PET-CT-positive, poor-risk, mCRPC. The interim analysis of ENZA-p with median follow-up 20 months showed improved PSA-progression-free survival with the addition of Lu-PSMA-617 to enzalutamide. Here, the investigators reported the secondary outcomes, overall survival, and health-related quality of life (HRQOL). After a median follow up of 34 months, overall survival was longer in the combination arm compared to the enzalutamide arm, with a median OS of 34 months compared to 26 months; with an HR of 0.55. Moreover, the combination improved both deterioration-free survival and health-related quality of life indicators for pain, fatigue, physical function, and overall health and quality of life compared to the control arm. Consistent with the primary analysis, the rPFS also favored the experimental arm with a median rPFS of 17 months compared to 14 months with a HR of 0.61. So, the addition of LuPSMA improved overall survival, and HRQOL in patients with high-risk mCRPC. Dr. Neeraj Agarwal: Thank you, Peter. Great summary, and promising results with Lu-177 and ARPI combination in first line treatment for mCRPC among patients who had two or more high risk features associated with early enzalutamide failure. Before we move on to bladder cancer, would you like to tell us about Abstract 15 titled, “World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration,” presented by Dr. Chad Tang?  Dr. Peter Hoskin: Sure. So, with metastatic-directed therapy (MDT), we have a number of phase 2 studies making up the database, and the X-MET collaboration aimed to consolidate all randomized data on oligometastatic solid tumors. This abstract presented pooled individual patient data from all the published trials involving patients with oligometastatic prostate cancer who received MDT alongside standard of care (SOC) against SOC alone. The analysis included data from five trials, encompassing 472 patients with oligometastatic prostate cancer, and followed for a median of 41 months. Patients were randomly assigned in a 1:1 ratio to receive either MDT plus SOC or SOC alone. The addition of MDT significantly improved PFS. The median PFS was 32 months with MDT compared to 14.9 months with SOC alone, with an HR of 0.45. Subgroup analyses further confirmed the consistent benefits of MDT across different patient groups. Regardless of factors like castration status, receipt of prior primary treatment, stage, or number of metastases, MDT consistently improved PFS. In patients with mHSPC, MDT significantly delayed the time to castration resistance by nine months, extending it to a median of 72 months compared to 63 months in the SOC group with an HR of 0.58. In terms of OS, the addition of MDT improved the 48-month survival rate by 12%, with OS rates of 87% in the MDT+SOC group compared to 75% in the SOC alone group. Dr. Neeraj Agarwal: Thank you, Peter. These data demonstrate that adding MDT to systemic therapy significantly improves PFS, rPFS, and castration resistance-free survival, reinforcing its potential role in the treatment of oligometastatic prostate cancer. So, let's switch gears to bladder cancer and start with Abstract 658 reporting the OS analysis of the CheckMate-274 trial. Would you like to tell us about this abstract?  Dr. Peter Hoskin: Yes, sure, Neeraj. This was presented by Dr. Matt Milowsky, and it was additional efficacy outcomes, including overall survival, from the CheckMate-274 trial which evaluated adjuvant nivolumab versus placebo in patients with high-risk muscle-invasive bladder cancer after radical surgery. The phase 3 trial previously demonstrated a significant improvement in disease-free survival with nivolumab. With a median follow-up of 36.1 months, disease-free survival was longer with nivolumab compared to placebo across all patients with muscle-invasive bladder cancer, reducing the risk of disease recurrence or death by 37%. Among patients who had received prior neoadjuvant cisplatin-based chemotherapy, nivolumab reduced this risk by 42%, whilst in those who had not received chemotherapy, the risk was reduced by 31%. Overall survival also favored nivolumab over placebo, reducing the risk of death by 30% in all patients with muscle-invasive bladder cancer and by 52% in those with tumors expressing PD-L1 at 1% or higher. Among patients who had received prior neoadjuvant chemotherapy, nivolumab reduced the risk of death by 26%, whilst in those who had not received chemotherapy, the risk was reduced by 33%. Alongside this, the safety profile remained consistent with previous findings. Dr. Neeraj Agarwal: Thank you, Peter, for such a nice overview of this abstract. These results reinforce adjuvant nivolumab as a standard of care for high-risk muscle-invasive bladder cancer, offering the potential for a curative outcome for our patients. Dr. Peter Hoskin: I agree with you Neeraj. Perhaps you would like to mention Abstract 659 titled, “Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA.” Dr. Neeraj Agarwal: Of course. Dr. Galsky presented additional outcomes from the phase 3 NIAGARA study, which evaluated perioperative durvalumab combined with neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. The study previously demonstrated a significant improvement in event-free survival and overall survival with durvalumab compared to chemotherapy alone, with a manageable safety profile and no negative impact on the ability to undergo radical cystectomy. Among the 1,063 randomized patients, those who received durvalumab had a 33% reduction in the risk of developing distant metastases or death and a 31% reduction in the risk of dying from bladder cancer compared to those who received chemotherapy alone. More patients who received durvalumab achieved a pathological complete response at the time of surgery with 37% compared to 28% in the chemotherapy-alone group. Patients who achieved a pathological complete response had better event-free survival and overall survival compared to those who did not. In both groups, durvalumab provided additional survival benefits, reducing the risk of disease progression or death by 42% and the risk of death by 28% in patients with a pathological complete response, while in those patients without a pathological complete response, the risk of disease progression or death was reduced by 23% and the risk of death by 16% when durvalumab was added to the chemotherapy. Immune-mediated adverse events occurred in 21% of patients in the durvalumab group compared to 3% in the chemotherapy-alone group, with grade 3 or higher events occurring in 3% compared to 0.2%. The most common immune-related adverse events included hypothyroidism in 10% of patients treated with durvalumab compared to 1% in the chemotherapy-alone group, and hyperthyroidism in 3% versus 0.8%. At the time of the data cutoff, these adverse events had resolved in 41% of affected patients in the durvalumab group and 44% in the chemotherapy-alone group. Dr. Peter Hoskin: Thank you, Neeraj, for the great summary. These findings further support the role of perioperative durvalumab as a potential standard of care for patients with muscle-invasive bladder cancer. Dr. Neeraj Agarwal: I concur with your thoughts, Peter. Before wrapping up the bladder cancer section, would you like to mention Abstract 664 reporting updated results from the EV-302 trial, which evaluated enfortumab vedotin in combination with pembrolizumab compared to chemotherapy as first-line treatment for patients with previously untreated locally advanced or metastatic urothelial carcinoma? Dr. Peter Hoskin: Yes, of course. Dr. Tom Powles presented updated findings from the EV-302 study, and in this abstract presented 12 months of additional follow-up for EV-302 (>2 y of median follow-up) and an exploratory analysis of patients with confirmed complete response (cCR). The study had a median follow-up of 29.1 months and previously demonstrated significant improvements in progression-free survival and overall survival with enfortumab vedotin and pembrolizumab. This is now the standard of care in global treatment guidelines. Among the 886 randomized patients, enfortumab vedotin and pembrolizumab reduced the risk of disease progression or death by 52% and the risk of death by 49% compared to chemotherapy. The survival benefit was consistent regardless of cisplatin eligibility or the presence of liver metastases. The confirmed objective response rate was higher with enfortumab vedotin and pembrolizumab at 67.5% compared to 44.2% with chemotherapy. The median duration of response was 23.3 months with enfortumab vedotin and pembrolizumab compared to 7.0 months with chemotherapy. A complete response was achieved in 30.4% of patients in the enfortumab vedotin and pembrolizumab group compared to 14.5% in the chemotherapy group, with the median duration of complete response not yet reached in the enfortumab vedotin and pembrolizumab group compared to 15.2 months in the chemotherapy group. Severe treatment-related adverse events occurred in 57.3% of patients treated with enfortumab vedotin and pembrolizumab compared to 69.5% in the chemotherapy group, while in patients who achieved a complete response, severe adverse events occurred in 61.7% of those treated with enfortumab vedotin and pembrolizumab compared to 71.9% with chemotherapy. Treatment-related deaths were reported in 1.1% of patients treated with enfortumab vedotin and pembrolizumab compared to 0.9% with chemotherapy, with no treatment-related deaths occurring in those who achieved a complete response. These findings clearly confirm the durable efficacy of enfortumab vedotin and pembrolizumab, reinforcing its role as the standard of care for the first-line treatment of patients with locally advanced or metastatic urothelial carcinoma, and no new safety concerns have been identified. Dr. Neeraj Agarwal: Thank you for this great summary. Moving on to kidney cancer, let's talk about Abstract 439 titled, “Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate-9ER trial.” Dr. Peter Hoskin: Sure. Dr. Motzer presented the final results from the phase 3 CheckMate-9ER trial, which compared the combination of cabozantinib and nivolumab against sunitinib in previously untreated advanced renal cell carcinoma. The data after more than five years follow-up show that the combination therapy provided sustained superior efficacy compared to sunitinib. In terms of overall survival, we see an 11-month improvement in median OS, 46.5 months for the cabo-nivo versus 35.5 months for sunitinib and a 42% reduction in the risk of disease progression or death, with median progression-free survival nearly doubling – that's 16.4 months in the combination group and 8.3 months with sunitinib. Importantly, the safety profile was consistent with the known safety profiles of the individual medicines, with no new safety concerns identified. Dr. Neeraj Agarwal: Great summary, Peter. These data further support the efficacy of cabo-nivo combination therapy in advanced renal cell carcinoma, which is showing a 11-month difference in overall survival. Dr. Peter Hoskin: Neeraj, before wrapping up this podcast, would you like to tell us about Abstract 618? This is titled “Prospective COTRIMS (Cologne trial of retroperitoneal lymphadenectomy in metastatic seminoma) trial: Final results.” Dr. Neeraj Agarwal: Sure, Peter. I would be delighted to. Dr Heidenrich from the University of Cologne in Germany presented the COTRIMS data evaluating retroperitoneal LN dissection in patients with clinical stage 2A/B seminomas. Seminomas are classified as 2A or B when the disease spreads to the retroperitoneal lymph nodes of up to 2 cm (CS IIA) or of more than 2 cm to up to 5 cm (CS 2B) in maximum diameter, respectively. They account for 10-15% of seminomas and they are usually treated with radiation and chemotherapy. However, radiation and chemo can be associated with long-term toxicities such as cardiovascular toxicities, diabetes, solid cancers, leukemia, particularly for younger patients. From this standpoint, Dr Heidenrich and colleagues evaluated unilateral, modified template, nerve-sparing retroperitoneal lymph node dissection as a less toxic alternative compared to chemo and radiation. They included 34 patients with negative AFP, beta-HCG, and clinical stage 2A/B seminomas. At a median follow-up of 43.2 months, the trial demonstrated great outcomes: a 99.3% treatment-free survival rate and 100% overall survival, with only four relapses. Antegrade ejaculation was preserved in 88% of patients, and severe complications such as grade 3 and 4 were observed in 12% of patients. Pathological analysis revealed metastatic seminoma in 85% of cases, with miR371 being true positive in 23 out of 24 cases and true negative in 100% of cases. It appears to be a valid biomarker for predicting the presence of lymph node metastases. These findings highlight retroperitoneal lymph node dissection is feasible; it has low morbidity, and excellent oncologic outcomes, avoiding overtreatment in 80% of patients and sparing unnecessary chemotherapy or radiotherapy in 10-15% of cases. Dr. Peter Hoskin: Great summary and important data on retroperitoneal lymphadenectomy in metastatic seminoma. These findings will help shape clinical practice. Any final remarks before we conclude today's podcast? Dr. Neeraj Agarwal: Before wrapping up this podcast, I would like to say that we have reviewed several abstracts addressing prostate, bladder, kidney cancers, and seminoma, which are impacting our medical practices now and in the near future. Peter, thank you for sharing your insights with us today. These updates are undoubtedly exciting for the entire GU oncology community, and we greatly appreciate your valuable contribution to the discussion and your leadership of the conference. Many thanks. Dr. Peter Hoskin: Thank you, Neeraj. Thank you for the opportunity to share this information more widely. I'm aware that whilst we have nearly 6,000 delegates, there are many other tens of thousands of colleagues around the world who need to have access to this information. And it was a great privilege to chair this ASCO GU25. So, thank you once again, Neeraj, for this opportunity to share more of this information that we discussed over those few days. Dr. Neeraj Agarwal: Thank you, Peter. And thank you to our listeners for joining us today. You will find links to the abstracts discussed today on the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.  Find out more about today's speakers:   Dr. Neeraj Agarwal    @neerajaiims    Dr. Peter Hoskin Follow ASCO on social media:      @ASCO on Twitter      ASCO on Bluesky  ASCO on Facebook      ASCO on LinkedIn      Disclosures: Dr. Neeraj Agarwal: Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas Dr. Peter Hoskin: Research Funding (Institution): Varian Medical Systems, Astellas Pharma, Bayer, Roche, Pfizer, Elekta, Bristol Myers  

Black Flag "Damaged I"Saccharine Trust "We Don't Need Freedom"MinuteFlag "Power Failure"Always August "Swim With Me"Meat Puppets "Oh Me"Divine Horsemen "Field of Stone"Minutemen "Little Man With A Gun In His Hand" (Acoustic Version)Saint Vitus "The Psychopath"Bad Brains "House of Suffering"Wurm "Nailed to the Wall"Bl'ast "It's In My Blood"Husker Du "59 Times The Pain"SWA "Islands In The Freeway"Slovenly "Diminished Ideal"Universal Congress Of "Chasing"Sonic Youth "Cotton Crown"

The “stoned ape hypothesis,” popularized by ethnobotanist Terence McKenna, suggests that the accidental consumption of psychedelic mushrooms by early hominids may have catalyzed rapid cognitive development, leading to significant advancements in language, abstract thinking, and social structures. While this speculative theory remains outside mainstream scientific consensus, it continues to spark curiosity and debate by linking consciousness expansion to dietary shifts in our evolutionary past.

Clement Bonnet discusses his novel approach to the ARC (Abstraction and Reasoning Corpus) challenge. Unlike approaches that rely on fine-tuning LLMs or generating samples at inference time, Clement's method encodes input-output pairs into a latent space, optimizes this representation with a search algorithm, and decodes outputs for new inputs. This end-to-end architecture uses a VAE loss, including reconstruction and prior losses. SPONSOR MESSAGES:***CentML offers competitive pricing for GenAI model deployment, with flexible options to suit a wide range of models, from small to large-scale deployments. Check out their super fast DeepSeek R1 hosting!https://centml.ai/pricing/Tufa AI Labs is a brand new research lab in Zurich started by Benjamin Crouzier focussed on o-series style reasoning and AGI. They are hiring a Chief Engineer and ML engineers. Events in Zurich. Goto https://tufalabs.ai/***TRANSCRIPT + RESEARCH OVERVIEW:https://www.dropbox.com/scl/fi/j7m0gaz1126y594gswtma/CLEMMLST.pdf?rlkey=y5qvwq2er5nchbcibm07rcfpq&dl=0Clem and Matthew-https://www.linkedin.com/in/clement-bonnet16/https://github.com/clement-bonnethttps://mvmacfarlane.github.io/TOC1. LPN Fundamentals [00:00:00] 1.1 Introduction to ARC Benchmark and LPN Overview [00:05:05] 1.2 Neural Networks' Challenges with ARC and Program Synthesis [00:06:55] 1.3 Induction vs Transduction in Machine Learning2. LPN Architecture and Latent Space [00:11:50] 2.1 LPN Architecture and Latent Space Implementation [00:16:25] 2.2 LPN Latent Space Encoding and VAE Architecture [00:20:25] 2.3 Gradient-Based Search Training Strategy [00:23:39] 2.4 LPN Model Architecture and Implementation Details3. Implementation and Scaling [00:27:34] 3.1 Training Data Generation and re-ARC Framework [00:31:28] 3.2 Limitations of Latent Space and Multi-Thread Search [00:34:43] 3.3 Program Composition and Computational Graph Architecture4. Advanced Concepts and Future Directions [00:45:09] 4.1 AI Creativity and Program Synthesis Approaches [00:49:47] 4.2 Scaling and Interpretability in Latent Space ModelsREFS[00:00:05] ARC benchmark, Chollethttps://arxiv.org/abs/2412.04604[00:02:10] Latent Program Spaces, Bonnet, Macfarlanehttps://arxiv.org/abs/2411.08706[00:07:45] Kevin Ellis work on program generationhttps://www.cs.cornell.edu/~ellisk/[00:08:45] Induction vs transduction in abstract reasoning, Li et al.https://arxiv.org/abs/2411.02272[00:17:40] VAEs, Kingma, Wellinghttps://arxiv.org/abs/1312.6114[00:27:50] re-ARC, Hodelhttps://github.com/michaelhodel/re-arc[00:29:40] Grid size in ARC tasks, Chollethttps://github.com/fchollet/ARC-AGI[00:33:00] Critique of deep learning, Marcushttps://arxiv.org/vc/arxiv/papers/2002/2002.06177v1.pdf

LI.FI introduces LI.FI 2.0. Abstract releases a post-mortem on the Cardex key leak. And applications open for Optimism's Onchain Builders retro funding round. Read more: https://ethdaily.io/650

John Trudell "Listening (Honor Song)"His Hero Is Gone "Monuments to Thieves"Destroy! "Stop Thinking and Follow"Aus-Rotten "When You Supoort These Fucking Bastards"Dystopia "Jarhead Fertilizer"Assuck "Civilization Comes/Civilization Goes"Doom "Cults of Human Sacrifice"Electro Hippies "Deception"A.P.F. Brigade "Anarchist Attack"Fuck The C.I.A. "Right or Wrong"Crass "Do They Owe Us A Living"Dead Prez "Propaganda" Chumbawamba "...Here's The Rest Of Your Life"The Coup featuring Dead Prez "Get Up"Amebix "Winter"Amebix "Beginning of the End"Armand Hammer "Slewfoot"Napalm Death Peel Session 13 September 1987

Send me a message here with feedback or topics you'd like to see covered on upcoming episodes! Or just say hello!Capturing great abstract or intimate natural landscapes is much more complex than most would expect. It isn't as easy as simply point-and-shoot. In this episode, photographer Andrew Mielzynski shares his advice on capturing these stunning abstract landscapes.This can be an excellent way to get some portfolio-quality images on days when the light just isn't cooperating, and I think it's a skill all outdoor photographers should hone in on.Links from this episode:Andrew's InstagramArtHelper.aiIf you're serious about becoming better at photography, the fastest way to do so is by joining me for an in-person workshop. Check my current workshop listings here.Find FREE photography tutorials on my YouTube channel.10 Landscape Photography Tips in 10 Minutes - FREE Video

Ending the gender insanity (5:17) What happened at the Superbowl? (21:30) Single and childless woman feels she got through 30’s without the rough experience parents had with their kids (29:00) We need to stop telling women they shouldn’t get pregnant and have babies. “Too many kids” “too close together” “you’ll be a geriatric mom”. (43:35) Resources mentioned: Paula Scanlan – “Lia Thomas” teammate https://omny.fm/shows/trending-with-timmerie-catholic-principles-applied/paula-scanlan-teammate-of-lia-thomas-the-locker-ro Who is St. Valentine – Timmerie shares his story https://omny.fm/shows/trending-with-timmerie-catholic-principles-applied/who-is-st-valentine Saints Podcast on Saint Valentine https://www.themerrybeggars.com/episodes/ts14-1-saint-valentine-episode-one Fertility specialist on helping women have kids – Dr. Caldwell https://relevantradio.com/2025/02/womens-health-and-fertility-hacks/ Link to studies about older maternal age and longevity in life: https://pmc.ncbi.nlm.nih.gov/articles/PMC4270889/ https://journals.lww.com/menopausejournal/Abstract/2020/11000/Maternal_age_at_last_birth_and_leukocyte_telomere.9.aspx?utm_source=chatgpt.com

Welcome to the inaugural episode of Critters Quest! (NEW JOB) We're diving headfirst into the volatile world of crypto, separating the signal from the noise. Today's quest includes: Bitcoin's potential pullback (and one analyst's $140k prediction!), Solana's explosive growth and SEC ETF acknowledgement, Ethereum's struggles, and the buzz around new projects like Berachain and Abstract. We'll also break down recent news like the OpenSea airdrop fiasco and Elon's Doge-related tax savings. Plus, a look at upcoming crypto conferences like ETHDenver, Paris Blockchain Week, and Bitcoin 2025. Join us as we navigate the crypto landscape, bringing clarity to the chaos.

>>RA event >>FB event ABSTRACT SCIENCE is back at PODLASIE CLUB with RAW CODE, a night focused on leftfield club sounds at the meeting of midwest dj culture + the UK hardcore continuum. Bristol UK heavyweight HODGE joins ABSCI/RAW CODE resident CHRIS WIDMAN + special guest TOYACOYAH. fri 14 february 2025 abstract science presents RAW... The post abstract science presents raw code with hodge, chris widman + toyacoyah at podlasie club chicago – fri 14 february 2025 appeared first on abstract science >> future music chicago.

Dr. Shaalan Beg and Dr. David Wang discuss key abstracts in GI cancers from the 2025 ASCO Gastrointestinal Cancers Symposium, including major advances in CRC, neoadjuvant approaches in esophageal cancer, and innovative studies on ctDNA. TRANSCRIPT Dr. Shaalan Beg: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Shaalan Beg. I'm a medical oncologist and an adjunct associate professor at UT Southwestern Medical Center in Dallas. Today, we're bringing you some key highlights from the 2025 ASCO Gastrointestinal Cancers Symposium, and I'm delighted to be joined by the chair of GI25, Dr. David Wang. Dr. Wang is a GI medical oncologist at the University of Michigan. Our full disclosures are available in the transcript of this episode.  Dr. Wang, thanks for coming on the podcast today. Dr. David Wang: Well, thank you. It's a pleasure to be here. Dr. Shaalan Beg: GI25 featured major therapeutic advances across the spectrum of GI malignancies, and it was exciting to hear about innovations and novel approaches that are shaping the future of our field. Before we start talking about specific abstracts, could you share some of your key highlights from the meeting? Dr. David Wang: Sure. Our theme this year was “Breaking Boundaries to Enhance Patient Centered Care.” Past years' themes have focused more on precision oncology, but we wanted to broaden our focus on patients and to be more holistic, which kind of led us into some of the Intersection [sessions] that we had. Each day started with a different Intersection. The first one was “Emerging Therapies in GI Cancers”, where invited speakers talked about bispecific antibody drug conjugates, theranostics, CAR T and other cell-based therapies. The second day was on “Personalized Risk Assessment for GI Cancers,” and this included looking at polygenic risk scores for colorectal cancer, microRNAs and liquid biopsies such as exosomes and pancreatic cancer and non-endoscopic screening modalities in esophageal cancer. And on our final day, we wanted to talk about “Integrative Oncology and Integrative Medicine,” looking at evidence-based uses of acupuncture and supplements in patients who are receiving treatment for cancer, mindfulness-based practices and exercise. And of course, we had a fantastic keynote talk by Dr. Pamela Kunz from the Yale School of Medicine titled, “Disrupting Gastrointestinal Oncology: Shattering Barriers with Inclusive Science.” She highlighted the intersection of science, patient care, and health and gender equity. And I would encourage your podcast listeners to access the lecture in ASCO's Meeting Library if they haven't yet had a chance to hear Dr. Kunz's wonderful lecture.  We were really happy this year because the attendance hit a new record. We had over 5,000 people attend either in person or virtually from their home or office, and we had almost 1,000 abstracts submitted to the meeting, so these were either record or near record numbers. We offered a lot of different networking opportunities throughout the meeting, and attending found these to be incredibly rewarding and important and this will continue to be an area of emphasis in future meetings. Dr. Shaalan Beg: Let's take a deeper dive into the exciting studies presented at GI25. The late breaking abstract LBA143 was CheckMate-8HW. This was the first results of NIVO + IPI versus NIVO monotherapy for MSI-high metastatic colorectal cancer. What are your thoughts about this study? Dr. David Wang: Yeah, so we know that colorectal cancer patients with MSI-high tumors don't necessarily respond well to chemotherapy. And we were fortunate because last year CheckMate-8HW actually looked at two different arms – so this was NIVO + IPI compared to standard of care chemotherapy and showed its very significant improvement in median progression-free survival. And that was actually published in the New England Journal of Medicine back in November of 2024. This year's presentation actually focused now on NIVO + IPI versus NIVO monotherapy. And as you know IPI+NIVO can be quite toxic. So this was an important analysis to be done. So we know that NIVO is definitely more easily tolerated. So what was interesting was that the 2-year and 3-year progression-free survival not surprisingly favored IPI+NIVO and this was statistically significant. And the overall response rate was also better with IPI+NIVO versus NIVO alone. I know we're always concerned about toxicities and there were higher grade 3 and 4 toxicity incidences in the combination arm versus the monotherapy arm, but overall, only about 28 additional events in several hundred patients treated. So I think that's well-tolerated. Our discussant Dr. Wells Messersmith actually said that, with this new data, he would consider doing combination immunotherapy in any patient that presented in the front line with MSI-high or deficient mismatch repair colorectal cancer that was metastatic. Dr. Shaalan Beg: One of the focuses for directing first-line therapy for colorectal cancer has been right and left sided colon cancer because we know these are two different cancers with their own unique molecular subtypes. We heard on Abstract 17, the DEEPER trial, the final analysis of modified FOLFOXIRI plus cetuximab versus bevacizumab for RAS wild-type and left sided metastatic colorectal cancer. How do you summarize the findings of this study and what should our readers be aware of? Dr. David Wang: Interestingly, this was a phase 2 study and the emphasis of the abstract was actually a subgroup analysis of those patients with RAS wild-type and BRAF wild-type as well as left sided cancers. So, I think the entire study enrolled 359 patients, but the analysis that was discussed at the meeting really focused on 178 patients that fit that characteristic. Very similar to what we've seen in prior studies, left-sided tumors have better response to cetuximab versus bevacizumab. And if you flip it so that you now are looking at right sided tumors, targeting EGFR is actually detrimental. The depth of response was better with cetuximab in these left sided RAS and BRAF mutant tumors. And so the lead author actually suggested that this could be a new first-line standard of care. And the question is, is there a benefit of doing this triple agent regimen with modified FOLFIRINOX? We know there's a lot more toxicity with that. Not clear that there's a benefit for that over FOLFOX, maybe in younger patients that could tolerate it. When our discussant, again Dr. Wells Messersmith, spoke about this, he said that, in his practice he would, again, favor cetuximab over bevacizumab in combination with chemo, these left-sided RAS and BRAF wild-type tumors, but that he would actually prefer a doublet versus a triplet chemo regimen, and that is consistent with the current NCCN guidelines. Dr. Shaalan Beg: Another area where colorectal cancer has been a wonderful model to study new technology has been in the area of circulating tumor DNA (ctDNA). And the BESPOKE CRC trial is looking to see if ctDNA can inform adjuvant treatment decisions for stage II and III colorectal cancer. And in Abstract 15, we heard final results of the BESPOKE CRC sub-cohort. What were the findings there? Dr. David Wang: BESPOKE CRC is another one of these important ctDNA studies. It was an observational study, not a randomized trial, but it did provide a lot of different insights to us. We know that there were over 1,700 patients enrolled, and so it was reported that this is the largest ctDNA study in colorectal cancer performed in the United States. And they were able to analyze over 1,100 patients.  Some of the key findings were that postoperative adjuvant therapy management decisions actually changed in 1 out of 6 patients, so that's pretty significant. In terms of surveillance, we know that patients who have ctDNA positivity, this is prognostic of recurrence. In terms of patients who have positive ctDNA post-surgery, it looked like, at least in this observational study, the majority of patients who received any benefit were those who had positive ctDNA. So adjuvant therapy, even in stage II and stage III patients seemed to only benefit those patients who have positive ctDNA. I think that does raise the question, and this also was brought up in the discussion, which is “Can we de-escalate adjuvant therapy in terms of patients who are ctDNA-negative post-op?” And Dr. Richard Kim from Moffitt felt that we are not yet there. Obviously, we need randomized control trials where we are taking ctDNA results and then randomizing patients to receive adjuvant or non-adjuvant to really know the difference.  Other questions that come up with use of ctDNA include: What do you do with these patients who turn positive? This study for BESPOKE actually followed patients out to two years after surgery. So what you do with a positive ctDNA result wasn't really clear. It seems to suggest that once you turn positive, patients go on to more intensive surveillance. You know, again as an observation, patients who did turn positive were able to go to metastasis-directed therapy much more quickly. And again, this was supposedly to improve their curative intent therapy. And I think the other question that has been brought up all the time is, is this really cost effective? Patients want to know, and we want to give patients that information, but I think we're still stuck with what to do with a positive ctDNA level in a patient that's on surveillance because no randomized control studies have actually suggested that we need to start systemic therapy right away. Dr. Shaalan Beg: Yeah. And I guess in terms of practice informing or practice changing, these results may not give us a clear answer. But because a lot of patients are asking for these tests, it does give us some real world experiences on what to expect in terms of conversion of these positive into negative and the outcome so we can have a shared decision making with our patients in the clinic and then come up with a determination on whether ctDNA for molecular residual disease is something which would be worthwhile for the care of our patient. But more to come, I guess, in coming years to answer different problems around this challenge. Dr. David Wang: Yes, I agree. Dr. Shaalan Beg: The BREAKWATER trial looked at the use of encorafenib, cetuximab and chemotherapy for BRAF V600E-mutant metastatic colorectal cancer. We've covered this combination for a second- third-line treatment in metastatic colorectal cancer previously. Abstract 16 from GI25 was evaluating the use of this regimen in the first-line space. Everyone was looking forward to these results, and what did the investigators present? Dr. David Wang: I think this is, as you mentioned, a nice follow up to later lines of therapy where Dr. Kopetz from MD Anderson pioneered use of encorafenib, cetuximab and binimetinib in the BEACON trial. Everybody was kind of curious what would happen now if you use encorafenib plus cetuximab plus chemotherapy in the first-line setting. And so this is an interim analysis that was pre-planned in the phase 3 open label BREAKWATER trial. And even though there were three arms, and so the three arms were encorafenib plus cetuximab, encorafenib plus cetuximab plus FOLFOX, or standard of care chemo, only two arms were presented in the abstract. So basically looking at encorafenib plus cetuximab and FOLFOX-6 versus standard of care therapy, and the overall response rate was statistically significant with a 60.9% overall response rate encorafenib plus cetuximab plus chemo arm versus standard of care chemo was only 40%. The interim overall survival also was different. It was 92% versus 87% at 6 months and 79% versus 66% at 12 months, again favoring the chemotherapy plus encorafenib plus cetuximab. In terms of the statistics, the p was 0.0004. However, the pre-plan analysis required the p-value to be 1x10 to the -8. And so even though this looks really good, it hasn't quite met its pre-specified significance level. The good thing is that this is only interim analysis and the study is ongoing with future analysis planned.  So the real question is: Does it matter when we actually use this regimen? We know that the regimen's approved in the second third-line setting. What about in the first line? And there was some preclinical data that the discussant reviewed that shows that patients actually benefit if this is done in the first-line setting. For example, there was some preclinical data showing that even FOLFIRI, for example, can upregulate RAS, which would make tumors more resistant to this combination. This was thought to be practice-changing in a patient that has B600E showing up treatment naive that we should probably consider this regimen. And actually this did receive accelerated FDA approval about a month ago. Dr. Shaalan Beg: Yeah, and for what it's worth, I put up a Twitter poll asking my Twitter followers on how the BREAKWATER trial results will change their approach for newly diagnosed BRAF mutated colorectal cancer. We got 112 responses; 72% said that they will incorporate encorafenib, cetuximab, FOLFOX for their frontline BRAF mutated patients. But 23% said that they would like to wait for overall survival results. Dr. David Wang: Wow, that's interesting. They really want that 1x10 to the -8. Dr. Shaalan Beg: I guess so. All right. Let's change gears and talk about esophageal cancer. LBA329 was the SCIENCE study which presented preliminary results from a randomized phase 3 trial comparing sintilimab and chemoradiotherapy plus sintilimab versus chemoradiotherapy for neoadjuvant resectable locally advanced squamous esophageal cancer. Where are we in this space? Dr. David Wang: Okay. So, yeah, this was an interesting trial. Again, just to set the context, esophageal squamous cell carcinoma is more prevalent in Asia. And the study sites as well as the patients were mostly from Asia. So this was again a phase 3 trial with interim results. They only rolled 146 out of the planned 420 for this interim analysis. And yeah, they're using immune checkpoint inhibitor that we don't use in the United States, sintilimab, combined with their two standards of neoadjuvant therapy, either chemotherapy, which is more common in Asia, or or chemoradiation, which is more common in the US and Western Europe, versus chemoradiation. And so they actually had two primary endpoints, but only were reporting one. So their two primary endpoints were pathCR and the other one was event-free survival. The event-free survival, again, was not reported at the meeting.  What they found was that in terms of pathCR rate, if you take the two arms that are really informative about that, chemoradiation plus sintilimab versus chemoradiation alone, the pathCR rate was 60% versus 47%. We know that chemo alone doesn't induce as much of a pathCR rate, and that was 13%. So it was found that the delta in terms of pathCR between the chemoradiation arms, one with sintilimab and one without, was significant. And this actually confirms data again from Asia, like for the ESCORT-NEO trial where it used another immune checkpoint inhibitor pembrolizumab in addition to neoadjuvant chemo.  So as our discussant for this abstract said, yes, we know that radiation combined with chemotherapy improves pathCR rates, but we have recent data from the ESOPEC trial, we don't know that that necessarily will translate to overall survival. So again, waiting for additional enrollments and longer term follow up before incorporating this into clinical care here. Dr. Shaalan Beg: So David, how do the results of the SCIENCE trial compare with our practice in the United States and ongoing studies asking questions for neoadjuvant therapy for esophageal carcinoma in the United States? Dr. David Wang: I think obviously immune checkpoint inhibitor in the new adjuvant setting is important. Jennifer Eads at UPenn is running that EA2174 which is looking at chemoradiation plus or minus nivolumab, and then in non-pathCR responders randomized to adjuvant nivolumab per CheckMate 577 or nivolumab with intensification adding ipilimumab. We know that the ESOPEC trial just came out, and was published actually during the meeting, and that really focuses on adenocarcinomas. So adenocarcinomas of the GE junction, distal esophagus, now, we would probably treat very similarly to gastric using perioperative FLOT. However, the standard in the US for esophageal squamous cell carcinoma remains neoadjuvant chemoradiation. We know that squamous cell carcinomas are more exquisitely sensitive to radiotherapy. And then obviously in those patients who don't achieve a pathologic complete response, the expectation would be that they would go on to receive nivolumab per CheckMate 577. Again, the thought is that these tumors are more sensitive to immunotherapy given their higher incidences of mutational changes. And so again, this kind of goes along with the positive results seen in the SCIENCE trial that we just discussed with sintilimab but also EFFECT-neo with pembrolizumab. Obviously, we await the results of Jennifer's trial. Dr. Shaalan Beg: And the last abstract I was hoping we could get your perspective on was Abstract 652, which is a Phase 3 study of everolimus plus lanreotide versus everolimus monotherapy for unresectable or recurrent gastroenteropancreatic neuroendocrine tumors, the STARTER-NET trial. What were the results of this study? Dr. David Wang: So, I just want to give a shout out because we did have a session at this year's GI ASCO that looked at more rare tumors. So appendiceal tumors, neuroendocrine tumors, those kinds of things. So again, I would encourage your listeners to listen to that session if they have interest in that. Another type of rare tumor was adenosquamous tumors.  But in terms of the STARTER-NET trial, this was again an interim analysis of his phase 3trial and it was looking at combining everolimus plus lanreotide versus everolimus. So we know that in pancreatic-gastric neuroendocrine tumors, if you have low Ki-67, a well differentiated tumor, that the standard of care really is a somatostatin analog, and sometimes if they're more aggressive, we kind of consider molecular targeted therapy with everolimus. This was asking the question of whether we should do the combination on the frontline. And what was interesting is in this study, the patients were actually more of a poor prognostic set. So they had Ki-67 up to 20% or these were patients that actually had multiple liver lesions. And what they found was a median for progression free survival was improved with a combination out to 29.7 months versus 11.5 months with the somatostatin analog alone, and that the overall response rate was 23% versus 8.3%, again, favoring the combination. If you looked at subgroup analysis, it was actually those patients who had Ki-67 greater than 10%, so the more aggressive tumors, or those with diffuse liver lesions that had the most benefit. So I think that would be the patient population I would consider this new combination with using would be those patients again with poorer prognosis neuroendocrine tumor phenotype. Dr. Shaalan Beg: Thank you very much, Dr. Wang, for sharing your insights with us today and your great work to build a robust GI Cancers Symposium this year. Dr. David Wang: Well, thank you. I mean that really is a cooperative effort. We appreciate all the members of the GI25 Program Committee as well as the ASCO staff that just made it an outstanding meeting. Dr. Shaalan Beg: And thank you to all our listeners for your time today. You'll find links to the abstracts discussed today on the transcript of this episode.  Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:  Dr. Shaalan Beg @ShaalanBeg  Dr. David Wang Follow ASCO on social media:   @ASCO on Twitter  @ASCO on BlueSky ASCO on Facebook   ASCO on LinkedIn   Disclosures:  Dr. Shaalan Beg:  Employment: Science 37  Consulting or Advisory Role: Ipsen, Array BioPharma, AstraZeneca/MedImmune, Cancer Commons, Legend Biotech, Foundation Medicine  Research Funding (Inst.): Bristol-Myers Squibb, AstraZeneca/MedImmune, Merck Serono, Five Prime Therapeutics, MedImmune, Genentech, Immunesensor, Tolero Pharmaceuticals  Dr. David Wang: Honoraria:  Novartis Consulting or Advisory Role: Novartis, Cardinal Health, Bristol-Myers Squibb, BeiGene, Eisai  

Felicity is a successful lawyer, but she wants a change. She tries painting and loves it. But there's a problem: everyone hates her paintings. Can she find the true shape of her art? Go to EasyStoriesInEnglish.com/Shape for the full transcript. Get episodes without adverts + bonus episodes at EasyStoriesInEnglish.com/Support. Your support is appreciated! Level: Beginner. Genre: Philosophical. Vocabulary: Shape, Sculpture, Law, Wrong (feeling), Art supplies, Landscape (painting), Portrait, Abstract, Bin. Setting: Modern. Word Count: 1397. Author: Ariel Goodbody. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, Michael Rearden explores the concept of the abstract mind and how embracing complex thought processes can enhance creativity, problem-solving, and personal development. The discussion dives into how individuals can tap into their abstract thinking abilities to break free from limitations and unlock deeper insights from the subconscious. Learn how understanding and nurturing the abstract mind can lead to greater innovation, critical thinking, and success in all areas of life. Read the Full Blog: http://www.revenconcepts.com/abstract-mind/#AbstractMind #CreativeThinking #MindsetShift #PersonalDevelopment #Innovation #ProblemSolving #CoachingInSession #GrowthMindset #UnlockYourPotential #Coaching Send us a MessageSupport the showWebsite: www.Revenconcepts.comEmail: Coachinginsession@gmail.com Don't forget to subscribe, leave a review, and share the podcast with others who would benefit from it!

Drs. Nico Cortes-Penfield (@Cortes-Penfield), Kerry LaPlante (@Kerry_LaPlante), Jessica Seidelman (@JessieLSeidel) join Dr. Julie Ann Justo (@julie_justo) to discuss the pesky slime that is biofilm in periprosthetic joint infections. They review biofilm composition & development, have an honest discussion about whether antibiotics can ever really eradicate it, and provide updates on the promising non-pharmacologic strategies on the horizon (bacteriophages, electromagnetism, & more). Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About X: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp References Nixing the Nidus: Managing Retained Sources in Prosthetic Joint Infections. Breakpoints Podcast Episode #67. Society of Infectious Diseases Pharmacists. Dosing Consult: Rifampin Part 1. Breakpoints Podcast Episode #104. Society of Infectious Diseases Pharmacists. Review on Staphylococcal biofilm development: Schilcher K, Horswill AR. 2020 Aug 12;84(3):e00026-19. doi: 10.1128/MMBR.00026-19. PMID: 32792334. Antibiotics can fail to kill biofilm cells even if they penetrate the biofilm: Singh R, et al. Pathog Dis. 2016 Aug;74(6):ftw056. doi: 10.1093/femspd/ftw056. Epub 2016 Jul 7. PMID: 27402781. Subinhibitory antibiotic concentrations can promote biofilm formation: Schilcher K, et al. Antimicrob Agents Chemother. 2016 Sep 23;60(10):5957-67. doi: 10.1128/AAC.00463-16. PMID: 27458233. Clinical and genetic risk factors for biofilm-forming Staphylococcus aureus: Luther MK, et al. Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02252-17. doi: 10.1128/AAC.02252-17. PMID: 29530854. Meta-analysis showing poor clinical outcomes with debridement, antibiotics, and implant retention (DAIR): Kunutsor SK, et al. J Infect. 2018 Dec;77(6):479-488. doi: 10.1016/j.jinf.2018.08.017. PMID: 30205122. Thieme L, et al. MBEC versus MBIC: the lack of differentiation between biofilm reducing and inhibitory effects as a current problem in biofilm methodology. Biol Proced Online 21, 18 (2019). https://doi.org/10.1186/s12575-019-0106-0. Ongoing trial investigating use of MBEC in the treatment of PJIs: Tillander JAN, et al. BMJ Open. 2022 Sep 15;12(9):e058168. doi: 10.1136/bmjopen-2021-058168. PMID: 36109038. Maale, G. Complete eradication of biofilm using low frequency electromagnetic force (EMF) and antibiotics at MIC. 34th Annual Meeting Musculoskeletal Infection Society. 2024 Aug. Abstract 1232 (see full program). Meta-analysis on bacteriophages for biofilm: Kovacs CJ, et al. Mil Med. 2024 May 18;189(5-6):e1294-e1302. doi: 10.1093/milmed/usad385. PMID: 37847552. Berking BB, et al. Biofilm disruption from within: light-activated molecular drill-functionalized polymersomes bridge the gap between membrane damage and quorum sensing-mediated cell death. ACS Biomater Sci Eng. 2024 Sep 9;10(9):5881-5891. doi: 10.1021/acsbiomaterials.4c01177. PMID: 39176452. Aboelnaga N, et al. Deciphering the dynamics of methicillin-resistant Staphylococcus aureus biofilm formation: from molecular signaling to nanotherapeutic advances. Cell Commun Signal. 2024 Mar 22;22(1):188. doi: 10.1186/s12964-024-01511-2. PMID: 38519959. Conway J, et al. Phase 1 study of the pharmacokinetics and clinical proof-of-concept activity of a biofilm-disrupting human monoclonal antibody in patients with chronic prosthetic joint infection of the knee or hip. Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0065524. doi: 10.1128/aac.00655-24. PMID: 39012102. Mulpur P, et al. Efficacy of intrawound vancomycin in prevention of periprosthetic joint infection after primary total knee arthroplasty: a prospective double-blinded randomized control trial. J Arthroplasty. 2024 Jun;39(6):1569-1576. doi: 10.1016/j.arth.2024.01.003. PMID: 38749600. Dong Y, et al. Synergy of ultrasound microbubbles and vancomycin against Staphylococcus epidermidis biofilm. J Antimicrob Chemother. 2013 Apr;68(4):816-26. doi: 10.1093/jac/dks490. PMID: 23248238. Miltenberg B, et al. Intraosseous Regional Administration of Antibiotic Prophylaxis for Total Knee Arthroplasty: A Systematic Review. J Arthroplasty. 2023 Apr;38(4):769-774. doi: 10.1016/j.arth.2022.10.023. PMID: 36280158. Viswanathan VK, et al. Intraosseous regional antibiotic prophylaxis in total joint arthroplasty (TJA): Systematic review and meta-analysis. J Clin Orthop Trauma. 2024 Oct 3;57:102553. doi: 10.1016/j.jcot.2024.102553. PMID: 39435324. SOLARIO trial: Dudareva M, et al. The European Bone and Joint Infection Society Meeting, 2024 Sept. SOLARIO trial press release from BoneSupportTM. 2024 Oct 3. Fehring TK, et al. Does treatment at a specialized prosthetic joint infection center improve the rate of reimplantation. J Arthroplasty. 2023 Jun;38(6S):S314-7. PMID 37004968. ROADMAP trial website. 2024.

Subscribe to Throwing Fits on Substack. Happy New Year! This week, Jimmy and Larry are cutting the last pod of 2024 with James hands-on review and a spirited debate of New Balance's 1906L aka snoafers, what's up with Kim Kardashian, MILF szn, the unfortunate tale of Lawrence's Christmas getting straight Grinched, witnessing holiday shopping meltdowns, Jeremy Strong wearing a ridiculous hat to dinner, James reviews A Complete Unknown and busts out an impressive Bob Dylan impression, the Mount Rushmore of Jews who changed their name to not sound Jewish, the math behind Lawrence's year in movies after hitting his goal and PR of watching 365 films, playing a new game of were you drunk when you took this Instagram photo, NYE fits, recapping Grailed's 2024 Marketplace Recap, Chuck is on the verge of potentially receiving a fantasy football last place punishment and much more.